Grail Inc
NASDAQ:GRAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Grail Inc
NASDAQ:GRAL
|
US |
Grail Inc
Grail is a healthcare diagnostics company that develops blood tests for finding cancer signals early, before symptoms appear. Its best-known product is a multi-cancer early detection test that analyzes fragments of DNA in a blood sample to look for signs of cancer and, in some cases, suggest where in the body the signal may be coming from. The company sells these tests to doctors, health systems, employers, and, in some cases, consumers through medical channels. Grail makes money mainly by selling tests and by building clinical evidence and testing programs that can be used in screening and preventive care. Its business sits between traditional lab testing and oncology: it is not treating cancer, but trying to change how cancer is found in the first place. What makes Grail different is that it is focused on a new category of screening rather than a standard lab menu. Its value depends on getting doctors, payers, and health systems to trust that a blood test can help catch hard-to-detect cancers earlier and fit into routine care.
Grail is a healthcare diagnostics company that develops blood tests for finding cancer signals early, before symptoms appear. Its best-known product is a multi-cancer early detection test that analyzes fragments of DNA in a blood sample to look for signs of cancer and, in some cases, suggest where in the body the signal may be coming from.
The company sells these tests to doctors, health systems, employers, and, in some cases, consumers through medical channels. Grail makes money mainly by selling tests and by building clinical evidence and testing programs that can be used in screening and preventive care. Its business sits between traditional lab testing and oncology: it is not treating cancer, but trying to change how cancer is found in the first place.
What makes Grail different is that it is focused on a new category of screening rather than a standard lab menu. Its value depends on getting doctors, payers, and health systems to trust that a blood test can help catch hard-to-detect cancers earlier and fit into routine care.
Revenue growth: GRAIL reported second-quarter revenue of $44.7 million, up 26% year over year, driven by stronger Galleri test volume and continued growth in both provider and employer channels.
Galleri momentum: Galleri screening revenue rose to $42.6 million, with test volume of more than 61,000, up 35% year over year; management said physician adoption continues to grow.
FDA path: Management said it continues to expect an FDA advisory committee in the fall and still expects potential approval in the first part of 2027.
Competition: Executives said newer MCED competitors are creating market confusion, but argued Galleri’s extensive screening-population data and low false positive rate set it apart.
Balance sheet: Cash ended the quarter at $861.6 million, including the $110 million Samsung strategic investment that closed in June.
International push: GRAIL highlighted the Samsung collaboration to commercialize Galleri in South Korea, with potential expansion into Japan and Singapore.